Nabriva Therapeutics plc Contracts & Agreements

Asset Purchase Agreement, dated as of July 30, 2023, by and among Nabriva Therapeutics plc, Nabriva Therapeutics Ireland DAC, Nabriva Therapeutics US, Inc., Nabriva Therapeutics... (Filed With SEC on July 31, 2023)

Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and J. Christopher Naftzger (Filed With SEC on July 7, 2023)

Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Daniel Dolan (Filed With SEC on July 7, 2023)

Separation and Release of Claims Agreement, by and between Nabriva Therapeutics US, Inc. and J. Christopher Naftzger (Filed With SEC on July 7, 2023)

Separation and Release of Claims Agreement, by and between Nabriva Therapeutics US, Inc. and Daniel Dolan (Filed With SEC on July 7, 2023)

Third Amendment to API Supply Agreement, dated November 11, 2022, by and between Nabriva Therapeutics Ireland Designated Activity Company and Hovione Limited (Filed With SEC on April 17, 2023)

Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Christine Guico-Pabia (Filed With SEC on April 17, 2023)

Separation and Release of Claims Agreement, by and between Nabriva Therapeutics US, Inc. and Christine Guico-Pabia (Filed With SEC on April 17, 2023)

Letter Agreement, dated January 31, 2023, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD International Business GmbH and Merck Sharp & Dohme LLC (Filed With SEC on February 6, 2023)

Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Steven Gelone (Filed With SEC on January 20, 2023)

Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Theodore Schroeder (Filed With SEC on January 20, 2023)

Separation and Release of Claims Agreement, by and between Nabriva Therapeutics US, Inc. and Steven Gelone (Filed With SEC on January 20, 2023)

Separation and Release of Claims Agreement, by and between Nabriva Therapeutics US, Inc. and Theodore Schroeder (Filed With SEC on January 20, 2023)

Third Amendment to Sales Promotion and Distribution Agreement, dated as of July 15, 2020, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD International... (Filed With SEC on August 3, 2022)

Side Agreement to Manufacturing Services Agreement, dated November 19, 2021, by and among Nabriva Therapeutics Ireland DAC and Patheon UK Ltd (Filed With SEC on March 29, 2022)

Form of Contingent RSU Award Agreement under the 2020 Share Incentive Plan, as amended (Filed With SEC on March 29, 2022)

Employment Agreement dated August 23, 2021 by and between Nabriva Therapeutics US, Inc. and Christine Guico-Pabia (Filed With SEC on November 9, 2021)

Employment Agreement dated August 24, 2021 by and between Nabriva Therapeutics US, Inc. and J. Christopher Naftzger (Filed With SEC on November 9, 2021)

2021 Inducement Share Incentive Plan, as amended (Filed With SEC on October 8, 2021)

Purchase Agreement dated September 24, 2021 between Nabriva Therapeutics plc and Lincoln Park Capital Fund, LLC (Filed With SEC on September 27, 2021)

Registration Rights Agreement dated September 24, 2021 between Nabriva Therapeutics plc and Lincoln Park Capital Fund, LLC (Filed With SEC on September 27, 2021)

Second Amendment to Sales Promotion and Distribution Agreement, dated as of April 12, 2021, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD... (Filed With SEC on August 5, 2021)

First Amendment to Sales Promotion and Distribution Agreement, dated as of July 15, 2020, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD International... (Filed With SEC on August 5, 2021)

Assignment, Assumption and Novation agreement, by and among Nabriva Therapeutics Ireland Designated Activity Company, Nabriva Therapeutics GmbH, Roivant Sciences Ltd., Roivant... (Filed With SEC on August 5, 2021)

Fourth Amendment to Loan and Security Agreement, dated as of June 2, 2021, by and among Nabriva Therapeutics Public Limited Company, Nabriva Therapeutics Ireland Designated... (Filed With SEC on August 5, 2021)

First Amendment to API Supply Agreement, dated August 4, 2021, by and between Nabriva Therapeutics Ireland Designated Activity Company and Hovione Limited (Filed With SEC on August 5, 2021)

Consulting Agreement, dated May 3, 2021, by and between Nabriva Therapeutics US, Inc. and Jennifer Schranz (Filed With SEC on May 6, 2021)

Open Market Sale AgreementSM, dated May 6, 2021, by and between Nabriva Therapeutics plc and Jefferies LLC (Filed With SEC on May 6, 2021)

Form of Share Option Agreement under the 2020 Share Incentive Plan, as amended (Filed With SEC on May 6, 2021)

Form of Restricted Share Unit Agreement under the 2020 Share Incentive Plan, as amended (Share Withholding) (Filed With SEC on May 6, 2021)

Form of Restricted Share Unit Agreement under the 2020 Share Incentive Plan, as amended (Automatic Sale) (Filed With SEC on May 6, 2021)

Form of Share Option Agreement under the 2021 Inducement Share Incentive Plan (Filed With SEC on May 6, 2021)

Amended and Restated Employment Agreement, by and between Nabriva Therapeutics US, Inc. and Theodore Schroeder, dated as of March 10, 2021 (Filed With SEC on March 11, 2021)

Third Amended and Restated Employment Agreement by and between Nabriva Therapeutics US, Inc. and Steven Gelone, dated as of March 10, 2021 (Filed With SEC on March 11, 2021)

2021 Inducement Share Incentive Plan (Filed With SEC on March 11, 2021)

Employment Agreement, by and between Nabriva Therapeutics US, Inc. and Daniel Dolan, dated as of March 10, 2021 (Filed With SEC on March 11, 2021)

First Amendment to License Agreement, dated October 29, 2021, by and among Nabriva Therapeutics Ireland DAC, Sinovant Sciences, Ltd., Nabriva Therapeutics GmbH and Roivant... (Filed With SEC on March 11, 2021)

Consulting Agreement, by and between Nabriva Therapeutics US, Inc. and Sender Consulting LLC, dated as of March 9, 2021 (Filed With SEC on March 11, 2021)

Amended and Restated Employment Agreement, by and between Nabriva Therapeutics US, Inc. and Robert Crotty, dated as of March 10, 2021 (Filed With SEC on March 11, 2021)

Description of the Registrants Securities Registered under Section 12 of the Exchange Act (Filed With SEC on March 11, 2021)

Form of Ordinary Share Warrant (Filed With SEC on March 1, 2021)

Form of Securities Purchase Agreement, dated March 1, 2021, by and among Nabriva Therapeutics plc and the purchasers party thereto (Filed With SEC on March 1, 2021)

Form of Pre-Funded Warrant (Filed With SEC on March 1, 2021)

Sublease Agreement, dated as of February 8, 2021, by and between Professional Payroll Solutions, LLC and Nabriva Therapeutics US, Inc (Filed With SEC on February 12, 2021)

Form of Securities Purchase Agreement, dated December 10, 2020, by and among Nabriva Therapeutics plc and the purchasers party thereto (Filed With SEC on December 14, 2020)

Retention Agreement, dated August 5, 2020, by and between Nabriva Therapeutics US, Inc. and Jennifer Schranz (Filed With SEC on November 5, 2020)

Sales Promotion and Distribution Agreement, dated as of July 15, 2020, by and among Nabriva Therapeutics Ireland Designated Activity Company, MSD International GmbH and Merck... (Filed With SEC on August 6, 2020)

Form of Securities Purchase Agreement, dated May 29, 2020, by and among Nabriva Therapeutics plc and the purchasers party thereto (Filed With SEC on June 1, 2020)

Form of Warrant (Filed With SEC on June 1, 2020)

Second Amendment to Loan and Security Agreement, dated as of January 8, 2020, by and among Nabriva Therapeutics Public Limited Company, Nabriva Therapeutics Ireland Designated... (Filed With SEC on March 12, 2020)

Description of the Registrants Securities Registered under Section 12 of the Exchange Act (Filed With SEC on March 12, 2020)

Form of Restricted Share Unit Agreement under the 2017 Share Incentive Plan (Share Withholding) (Filed With SEC on March 12, 2020)

Third Amendment to Loan and Security Agreement, dated as of March 11, 2020, by and among Nabriva Therapeutics Public Limited Company, Nabriva Therapeutics Ireland Designated... (Filed With SEC on March 12, 2020)

Form of Share Option / Cash Settled Share Appreciation Right Agreement under the 2020 Share Incentive Plan (Filed With SEC on March 12, 2020)

2020 Share Incentive Plan (Filed With SEC on March 12, 2020)

Form of Warrant (Filed With SEC on December 20, 2019)

Form of Securities Purchase Agreement, dated December 20, 2019, by and among Nabriva Therapeutics plc and the purchasers party thereto (Filed With SEC on December 20, 2019)

First Amendment to Loan and Security Agreement, dated as of September 26, 2019, by and among Nabriva Therapeutics Public Limited Company, Nabriva Therapeutics Ireland Designated... (Filed With SEC on November 12, 2019)

Open Market Sale AgreementSM, dated June 25, 2019, by and between Nabriva Therapeutics plc and Jefferies LLC (Filed With SEC on June 25, 2019)

Agreement for the Commercial Supply of Products by and between Arran Chemical Company Limited and Nabriva Therapeutics Ireland DAC, dated as of November 12, 2018 (Filed With SEC on March 12, 2019)

Active Pharmaceutical Ingredient Supply Agreement by and between Nabriva Therapeutics Ireland DAC and Hovione Limited, dated as of November 23, 2018 (Filed With SEC on March 12, 2019)

Employment Agreement, by and between Nabriva Therapeutics US, Inc. and Jennifer Schranz, dated as of March 21, 2018 (Filed With SEC on March 12, 2019)

Loan and Security Agreement, dated as of December 20, 2018, by and among Nabriva Therapeutics plc, Nabriva Therapeutics Ireland DAC, certain other subsidiaries of Nabriva... (Filed With SEC on March 12, 2019)

Second Amended and Restated Employment Agreement by and between Nabriva Therapeutics US, Inc. and Steven Gelone, dated as of July 24, 2018 (Filed With SEC on November 6, 2018)

Stock Purchase Agreement by and among SG Pharmaceuticals, Inc., the Sellers named on Annex A, and Julia Feliciano, as Sellers Representative, dated as of May 5, 2015 (Filed With SEC on November 6, 2018)

License Agreement by and between ICPD Holdings, LLC and Evelyn J. Ellis-Grosse and Zavante Therapeutics, Inc., dated as of March 1, 2014 (Filed With SEC on November 6, 2018)

Office Lease by and between AGP Sorrento R&D, LP and Zavante Therapeutics, Inc., dated as of June 16, 2016 (Filed With SEC on November 6, 2018)

Manufacturing and Supply Agreement by and between Zavante Therapeutics, Inc. and Ercros, S.A., dated as of July 28, 2016 (Filed With SEC on November 6, 2018)

Amended and Restated Three-Way Agreement by and between Laboratorios ERN, S.A, Ercros, S.A., and Zavante Therapeutics, Inc., dated as of July 28, 2016 (Filed With SEC on November 6, 2018)

Amended and Restated Pharmaceutical Manufacturing and Exclusive Supply Agreement by and between Laboratorios ERN, S.A. and Zavante Therapeutics, Inc. dated as of July 28, 2016, as... (Filed With SEC on November 6, 2018)

Manufacturing and Supply Agreement by and between Zavante Therapeutics, Inc. and Fisiopharma, S.r.l., dated as of April 14, 2017 (Filed With SEC on November 6, 2018)

Commercial Packaging Agreement by and between Zavante Therapeutics, Inc. and AndersonBrecon Inc., d/b/a PCI of Illinois, dated as of December 26, 2017 (Filed With SEC on November 6, 2018)

Packaging and Supply Agreement by and between Sharp Corporation and Nabriva Therapeutics US, Inc., dated as of August 30, 2018 (Filed With SEC on November 6, 2018)

Underwriting Agreement, dated July 26, 2018, by and among Nabriva Therapeutics plc and Morgan Stanley & Co. LLC, as representative of the underwriters named therein (Filed With SEC on August 1, 2018)

Agreement and Plan of Merger dated as of July 23, 2018, by and among Nabriva Therapeutics plc, Zuperbug Merger Sub I, Inc., Zuperbug Merger Sub II, Inc., Zavante Therapeutics,... (Filed With SEC on July 25, 2018)

Transition, Separation and Release of Claims Agreement, by and between Nabriva Therapeutics US, Inc. and Colin Broom, dated as of July 23, 2018 (Filed With SEC on July 25, 2018)

Employment Agreement, by and between Nabriva Therapeutics US, Inc. and Theodore Schroeder, dated as of July 23, 2018 (Filed With SEC on July 25, 2018)

License Agreement, dated March 26, 2018, by and among Nabriva Therapeutics Ireland DAC, Sinovant Sciences, Ltd., Nabriva Therapeutics GmbH and Roivant Sciences, Ltd (Filed With SEC on May 8, 2018)

Key Intermediate Supply Agreement, dated of August 28, 2017 by and among Nabriva Therapeutics Ireland DAC, and SEL Biochem Xinjiang Co., Ltd, and Fountain International... (Filed With SEC on March 16, 2018)

Controlled Equity OfferingSM Sales Agreement, dated March 16, 2018, by and between Nabriva Therapeutics plc and Cantor Fitzgerald & Co (Filed With SEC on March 16, 2018)

Master Agreement for the Manufacture, Packaging and Supply of Products, dated August 7, 2017, by and between ALMAC Pharma Services Limited and Nabriva Therapeutics Ireland DAC (Filed With SEC on March 16, 2018)

Manufacturing Services Agreement, dated May 8, 2017, by and between Patheon UK Limited and Nabriva Therapeutics AG (Filed With SEC on March 16, 2018)

Form of Restricted Share Unit Agreement under the 2017 Share Incentive Plan (Filed With SEC on February 2, 2018)

Form of Share Option Agreement under the 2017 Share Incentive Plan (Filed With SEC on February 2, 2018)

2017 Share Incentive Plan (Filed With SEC on November 9, 2017)

Underwriting Agreement, dated September 19, 2017, by and among Nabriva Therapeutics plc and Morgan Stanley & Co. LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as... (Filed With SEC on September 20, 2017)

SEPARATION AND RELEASE OF CLAIMS AGREEMENT (Filed With SEC on August 31, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on August 7, 2017)

Category

Industry

Companies

Contracts

Nabriva Therapeutics plc Contracts & Agreements